Therapeutics such as Anakinra (IL-1R antagonist), Tocilizumab (anti-IL-6 receptor), Secukinumab (anti-IL17A), and Belimumab (anti-B-cell activating factor) are routinely used in a variety of inflammatory diseases such as gout, SLE, psoriasis, Crohn’s disease, and RA. This evidence concerns the gene IL1R1 and rheumatoid arthritis.